Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications
Hand-out
Press Releases
December 10, 2024

Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications

FREDERICK, Md., Dec. 10, 2024 /PRNewswire/ -- Theradaptive, a privately held, clinical stage biologics company developing protein therapeutics for spine, orthopedics, soft tissue repair, and targeted immuno-oncology, announced today that

bradford

The Bradford Era

Local & Social